Updated time: 2024-09-23 11:03:26
12A-1040225
US 11,214,774 B2、JP 特許字第6542468號、EP 3288963
EGFR is an important driver gene in lung cancer. EGFR tyrosine kinase inhibitors (EGFR-TKIs) play a key role in lung cancer therapy. Nevertheless, the continuously evolving drug resistance following EGFR-TKI treatment remains an unsolved issue in clinical practice. This discovery may provide an alternative strategy for EGFR inhibition.
Drugs that are developed based on the new mechanism discovered inhibit EGFR through different biochemical mechanism from small molecule drugs and may provide an alternative strategy in terms of EGFR-targeted therapy.
EGFR-driven cancers, such as lung cancer.
Pan-Chyr Yang, Pei-Ying Lin, Bo-Tsang Huang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

PINK1 is a Tumor Suppressor in EGFR-driven Carcinogenesis